Sunrise Genetics Inc.

sunrisegenetics.com

Sunrise Genetics (HEMPGENE | MARIGENE) is based out of Colorado and specializes in the development and application of different genomic tools used to advance the breeding efforts of Cannabis. We are a small, collaborative group of Cannabis scientists, professionals, and advocates, who partner with industry-leading breeders and cultivators to apply evolving genomic knowledge to target improvement of desired traits, accelerate breeding, and discover the commercial and industrial potential of Cannabis.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BOLT BIOTHERAPEUTICS RAISES $93.5 MILLION SERIES C FINANCING

Bolt Biotherapeutics | July 06, 2020

news image

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the innate immune system to treat cancer, today announced the closing of an oversubscribed $93.5 million Series C financing. Led by Sofinnova Investments, the Series C financing included participation from new investors RA Capital Management, Surveyor Capital (a Citadel Company), Rock Springs Capital, Samsara BioCapital and Pfi...

Read More

KYTOPEN PARTNERS WITH CAMBRIDGE CONSULTANTS ON FLOWFECT

Genetic Engineering and Biotechnology News | January 28, 2020

news image

MIT spin-out company Kytopen signed a deal with Cambridge Consultants to co-develop the FlowfectTM system, a scalable process that reportedly yields billions of engineered cells in minutes. The product will streamline the engineering of a wide array of human and human-derived cells for use in next-generation cell therapies, with the goal of expanding access to new medicines, says Paulo Garcia, CEO and co-founder of Kytopen....

Read More

CELL AND GENE THERAPY

INNOVENT ANNOUNCES FIRST PATIENT DOSING OF UNIVERSAL MODULAR CAR-T CELL PRODUCT IBI345

Innovent Biologics | February 21, 2022

news image

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced the first patient dosing for its first-in-class IgG-based universal "modular" Claudin 18.2-targeting chimeric antigen receptor T (CAR-T) cell product (development code: IBI345) for the treatment of advanced Claudin18.2-positive solid tumors in an investigator-...

Read More

CELL AND GENE THERAPY

GAMMA BIOSCIENCES AND LONZA COLLABORATE TO CO-DEVELOP REAGENTS FOR CLINICAL CELL SELECTION IN THE COCOON® PLATFORM

Gamma Biosciences | October 13, 2022

news image

Gamma Biosciences, a leading provider of tools and technologies for cell and gene therapy manufacturing, through their BioMagnetic Solutions business announced a strategic collaboration with Lonza. Under the multi-year agreement, BioMagnetic Solutions will supply its proprietary research and cGMP manufacturing grade FerroSelect™ reagents to Lonza for use in developing CAR-T and other immunotherapeutic products using Lonza's Cocoon® Platform. " Read More

news image

BOLT BIOTHERAPEUTICS RAISES $93.5 MILLION SERIES C FINANCING

Bolt Biotherapeutics | July 06, 2020

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the innate immune system to treat cancer, today announced the closing of an oversubscribed $93.5 million Series C financing. Led by Sofinnova Investments, the Series C financing included participation from new investors RA Capital Management, Surveyor Capital (a Citadel Company), Rock Springs Capital, Samsara BioCapital and Pfi...

Read More
news image

KYTOPEN PARTNERS WITH CAMBRIDGE CONSULTANTS ON FLOWFECT

Genetic Engineering and Biotechnology News | January 28, 2020

MIT spin-out company Kytopen signed a deal with Cambridge Consultants to co-develop the FlowfectTM system, a scalable process that reportedly yields billions of engineered cells in minutes. The product will streamline the engineering of a wide array of human and human-derived cells for use in next-generation cell therapies, with the goal of expanding access to new medicines, says Paulo Garcia, CEO and co-founder of Kytopen....

Read More
news image

CELL AND GENE THERAPY

INNOVENT ANNOUNCES FIRST PATIENT DOSING OF UNIVERSAL MODULAR CAR-T CELL PRODUCT IBI345

Innovent Biologics | February 21, 2022

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced the first patient dosing for its first-in-class IgG-based universal "modular" Claudin 18.2-targeting chimeric antigen receptor T (CAR-T) cell product (development code: IBI345) for the treatment of advanced Claudin18.2-positive solid tumors in an investigator-...

Read More
news image

CELL AND GENE THERAPY

GAMMA BIOSCIENCES AND LONZA COLLABORATE TO CO-DEVELOP REAGENTS FOR CLINICAL CELL SELECTION IN THE COCOON® PLATFORM

Gamma Biosciences | October 13, 2022

Gamma Biosciences, a leading provider of tools and technologies for cell and gene therapy manufacturing, through their BioMagnetic Solutions business announced a strategic collaboration with Lonza. Under the multi-year agreement, BioMagnetic Solutions will supply its proprietary research and cGMP manufacturing grade FerroSelect™ reagents to Lonza for use in developing CAR-T and other immunotherapeutic products using Lonza's Cocoon® Platform. " Read More